Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARTV vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARTV Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

ARTV Overall Winner 6-Pillar Tally: ARTV 3 – 2 CVM (1 Tie) Matrix Metrics: ARTV 4 – 4 CVM

As of Nov 16, 2026, Artiva Biotherapeutics, Inc. (ARTV) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ARTV carries a Unified Composite Score of 60.0/100 (BUY) at $3.95 (N/M Forward P/E, 0.0% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ARTV earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. CVM 56.6/100 HOLD) and 1.71β · 116% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ARTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.6); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARTV vs CVM
ARTV NASDAQ Head-to-Head Winner
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.95
-1.5% 1D
Market Cap $195.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.71β · 116% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 76.0 Fund 66.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.3%), weak momentum, RSI 23
RSI-14: 22.6 · SMA20: $4.69 · SMA50: $6.51
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (ARTV 3 – 2 CVM)

Columns: Metric · ARTV · CVM
1. Valuation Multiples CVM
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M 1.12x
EV / Revenue N/M N/M
2. Growth & Scale CVM
Revenue Growth (YoY) -100.0% -62.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $28,558
Market Cap $195.8M $20.9M
3. Profitability & Quality ARTV
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -43.6% -252.5%
4. Balance Sheet & Cash Flow ARTV
Cash Generation (TTM) -$87M -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARTV
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 53.6% (<1st %ile) N/A (N/A)
Put/Call OI Skew 0.37x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARTV (4) vs CVM (4)
Institutional Metric ARTV CVM Criterion Row Edge
Market Capitalization
Scale
$195.8M $20.9M Larger Scale ARTV
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
-100.0% -62.7% Higher Growth CVM
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-43.6% -252.5% Higher ROE ARTV
52-Week Range Position
Momentum
8% ($3–$15) 10% ($1–$8) Stronger Trend CVM
Beta / 30D Volatility
Risk Regime
1.71β · 116% Vol 0.65β · 120% Vol Lower Realized Risk ARTV
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 56.6 / 100 (HOLD) Higher Composite ARTV
Trailing 12M Revenue (USD)
Operating Scale
N/A $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$87M ($52M Net Cash) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVM +21.31 pp
ARTV: -32.48% · CVM: -11.17%
3M Horizon CVM +66.18 pp
ARTV: -66.18% · CVM: +0.0%
6M Horizon CVM +49.6 pp
ARTV: -57.16% · CVM: -7.56%
1Y Horizon ARTV +97.52 pp
ARTV: +21.54% · CVM: -75.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARTV Revenue CVM Revenue ARTV Op. Margin CVM Op. Margin Margin Leader
FY2011 N/A $0M N/A -1881.0% CVM
FY2012 N/A $0M N/A -6772.3% CVM
FY2013 N/A $0M N/A -12450.1% CVM
FY2014 N/A $0M N/A -9721.4% CVM
FY2023 $30M N/A -93.2% N/A ARTV
FY2024 $0M N/A -26805.6% N/A ARTV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARTV BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 53.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.37x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ARTV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARTV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $195.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARTV vs CVM Key Questions & Quantitative Answers

As of Nov 16, 2026, Artiva Biotherapeutics, Inc. (ARTV) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ARTV carries a Unified Composite Score of 60.0/100 (BUY) at $3.95 (N/M Forward P/E, 0.0% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ARTV earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. CVM 56.6/100 HOLD) and 1.71β · 116% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ARTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.6); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVM leads the Growth & Scale pillar: ARTV posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2011 to FY2024), ARTV cumulative revenue shifted N/A while CVM shifted N/A. In operating R&D and SG&A reinvestment, ARTV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. ARTV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARTV (-43.6% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ARTV carries 53.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.37x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.71β · 116% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.